Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Makenzie Vorderbruggen

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|May 25, 2024
PROTACs in Ovarian Cancer: Current Advancements and Future PerspectivesMakenzie Vorderbruggen, Carlos A Velázquez-Martínez, Amarnath Natarajan, et al.
Journal of Ovarian Research|May 4, 2024
NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cellsCassie Liu, Makenzie Vorderbruggen, Catalina Muñoz-Trujillo, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|May 25, 2024
PROTACs in Ovarian Cancer: Current Advancements and Future PerspectivesMakenzie Vorderbruggen, Carlos A Velázquez-Martínez, Amarnath Natarajan, et al.
Journal of Ovarian Research|May 4, 2024
NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cellsCassie Liu, Makenzie Vorderbruggen, Catalina Muñoz-Trujillo, et al.
Pageof 1